ABSTRACT
Low red blood cell (RBC) membrane content of EPA and DHA, i.e., the omega-3 index (O3I), and elevated RBC distribution width (RDW) are risk factors for all-cause mortality. O3I and RDW are related with membrane fluidity and deformability. Our objective was to determine if there is a relationship between O3I and RDW in healthy adults. Subjects without inflammation or anemia, and with values for O3I, RDW, high-sensitivity C-reactive protein (CRP), body mass index (BMI), age and sex were identified (n = 25,485) from a clinical laboratory dataset of > 45,000 individuals. RDW was inversely associated with O3I in both sexes before and after (both p < 0.00001) adjusting models for sex, age, BMI and CRP. Stratification by sex revealed a sex-O3I interaction with the RDW-O3I slope (p < 0.00066) being especially steep in females with O3I ≤ 5.6%. In healthy adults of both sexes, the data suggested that an O3I of > 5.6% may help maintain normal RBC structural and functional integrity.
Subject(s)
Cell Size , Docosahexaenoic Acids/blood , Eicosapentaenoic Acid/blood , Erythrocyte Membrane/chemistry , Erythrocytes/ultrastructure , Health Status , Adult , Aged , Body Mass Index , C-Reactive Protein/analysis , Cross-Sectional Studies , Dietary Supplements , Female , Healthy Volunteers , Humans , Male , Middle Aged , Risk FactorsABSTRACT
BACKGROUND: Composite lipid emulsions containing soybean oil (30%), medium-chain triglycerides (30%), olive oil (25%), and fish oil (15%) (SMOF) are now widely used. OBJECTIVES: We aimed to evaluate the tolerance, the efficiency, and the erythrocyte fatty acid (FA) profile for children on long-term home parenteral nutrition (HPN) receiving a composite fish oil-based emulsion (FOLE). METHODS: At baseline, children (n = 46) with severe intestinal failure highly dependent on parenteral nutrition (PN) for ≥1 y were included in the study when they had received the composite FOLE for >6 mo. Out of this baseline group, only 25 children remained highly PN-dependent (SMOF1, n = 25) and could be assessed a second time, 2.4 y later (SMOF2, n = 25). An independent control group ("weaned off PN" group; n = 24) included children who had been weaned off PN for >2 y (median: 4 y). RBC-FA composition was established by GC-MS. Growth parameters, plasma citrulline, conjugated bilirubin, FA profiles, and the Holman ratio (20:3ω-9/20:4ω-6) were compared between groups. RESULTS: No difference for growth parameters, citrulline, and bilirubin was observed between the SMOF groups after 2.4 y (0.2 < P < 0.8). The weaned-off group did not differ from the SMOF groups for growth parameters (0.2 < P < 0.4) but citrulline was higher (P < 0.0001) and conjugated bilirubin lower (P < 0.01). The composite FOLE induced higher proportions of EPA (20:5n-3) (8.4% ± 2.9%) and DHA (22:6n-3) (11.7% ± 2.2%) than what was observed in weaned-off children (0.8% ± 0.4% and 6.6% ± 2.3%, respectively) but lower proportions of arachidonic acid (20:4n-6). However, the Holman ratio did not vary between groups (P = 0.9), whereas the PUFA concentrations varied widely. CONCLUSIONS: Long-term use of the composite FOLE was well tolerated in HPN-dependent children. The RBC-FA profile alterations were consistent with the ω-3 PUFA-enriched composition of this emulsion without evidence of essential FA deficiency.
Subject(s)
Erythrocyte Membrane/chemistry , Fatty Acids, Omega-3/administration & dosage , Fatty Acids/blood , Intestinal Failure/blood , Parenteral Nutrition, Home/methods , Bilirubin/blood , Child , Child, Preschool , Cross-Sectional Studies , Fat Emulsions, Intravenous , Female , Fish Oils/administration & dosage , Food, Fortified , Humans , Intestinal Failure/therapy , Male , Olive Oil/administration & dosage , Soybean Oil/administration & dosage , Treatment Outcome , Triglycerides/administration & dosageABSTRACT
Immunotherapy is currently an important adjuvant therapy for malignant tumors besides surgical treatment. However, the heterogeneity and low immunogenicity of the tumor are two main challenges of the immunotherapy. Here, we have constructed a nanoplatform (CP@mRBC-PpIX) to realize reversion of the tumor acidosis and hypoxia through alkali and oxygen generation triggered by tumor acidosis. By targeting tumor universal features other than endogenous biomarkers, it was found that CP@mRBC-PpIX could polarize tumor-associated macrophages to anti-tumor M1 phenotype macrophages to enhance tumor immune response. Furthermore, under regional light irradiation, the reactive oxygen species produced by photosensitizers located in CP@mRBC-PpIX could increase the immunogenicity of tumors, so that tumor changes from an immunosuppressive "cold tumor" to an immunogenic "hot tumor," thereby increasing the infiltration and response of T cells, further amplifying the effect of immunotherapy. This strategy circumvented the problem of tumor heterogeneity to realize a kind of broad-spectrum immunotherapy, which could effectively prevent tumor metastasis and recurrence.
Subject(s)
Antineoplastic Agents/therapeutic use , Erythrocyte Membrane/chemistry , Metal Nanoparticles/therapeutic use , Neoplasms/drug therapy , Protoporphyrins/therapeutic use , Tumor Microenvironment/drug effects , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/radiation effects , Cell Line, Tumor , Copper/chemistry , Copper/therapeutic use , Humans , Immunity/drug effects , Immunotherapy , Light , Lymphocyte Activation/drug effects , Macrophages/drug effects , Metal Nanoparticles/chemistry , Metal Nanoparticles/radiation effects , Mice, Inbred C57BL , Neoplasms/immunology , Neoplasms/metabolism , Peroxides/chemistry , Peroxides/therapeutic use , Photosensitizing Agents/chemistry , Photosensitizing Agents/radiation effects , Photosensitizing Agents/therapeutic use , Protoporphyrins/chemistry , Protoporphyrins/radiation effects , Reactive Oxygen Species/metabolism , T-Lymphocytes/drug effectsABSTRACT
Low heart rate variability (HRV) is independently associated with increased risk of sudden cardiac death (SCD) and all cardiac death in haemodialysis patients. Long chain n-3 polyunsaturated fatty acids (LC n-3 PUFA) may exert anti-arrhythmic effects. This study aimed to investigate relationships between dialysis, sleep and 24 h HRV and LC n-3 PUFA status in patients who have recently commenced haemodialysis. A cross-sectional study was conducted in adults aged 40-80 with chronic kidney disease (CKD) stage 5 (n = 45, mean age 58, SD 9, 20 females and 25 males, 39% with type 2 diabetes). Pre-dialysis blood samples were taken to measure erythrocyte and plasma fatty acid composition (wt % fatty acids). Mean erythrocyte omega-3 index was not associated with HRV following adjustment for age, BMI and use of ß-blocker medication. Higher ratios of erythrocyte eicosapentaenoic acid (EPA) to docosahexaenoic acid (DHA) were associated with lower 24 h vagally-mediated beat-to-beat HRV parameters. Higher plasma EPA and docosapentaenoic acid (DPAn-3) were also associated with lower sleep-time and 24 h beat-to-beat variability. In contrast, higher plasma EPA was significantly related to higher overall and longer phase components of 24 h HRV. Further investigation is required to investigate whether patients commencing haemodialysis may have compromised conversion of EPA to DHA, which may impair vagally-mediated regulation of cardiac autonomic function, increasing risk of SCD.
Subject(s)
Fatty Acids, Omega-3/blood , Heart Rate , Kidney Failure, Chronic/physiopathology , Kidney Failure, Chronic/therapy , Renal Dialysis , Adult , Aged , Aged, 80 and over , Autonomic Nervous System/physiopathology , Cross-Sectional Studies , Death, Sudden, Cardiac/etiology , Diabetes Mellitus, Type 2/complications , Docosahexaenoic Acids/blood , Eicosapentaenoic Acid/blood , Erythrocyte Membrane/chemistry , Female , Heart Disease Risk Factors , Humans , Kidney Failure, Chronic/complications , Male , Middle Aged , Pilot Projects , SleepABSTRACT
This work presents a semi-quantitative spectroscopic approach, including FTIR-ATR and Raman spectroscopies, for the biochemical analysis of red blood cells (RBCs) supported by the biochemical, morphological and rheological reference techniques. This multi-modal approach provided the description of the RBC alterations at the molecular level in a model of accelerated aging induced by administration of D-galactose (D-gal), in comparison to natural aging. Such an approach allowed to conclude that most age-related biochemical RBC membrane changes (a decrease in lipid unsaturation and the level of phospholipids, or an increase in acyl chain shortening) as well as alterations in the morphological parameters and RBC deformability are well reflected in the D-gal model of accelerated aging. Similarly, as in natural aging, a decrease in LDL level in blood plasma and no changes in the fraction of glucose, creatinine, total cholesterol, HDL, iron, or triglycerides were observed during the course of accelerated aging. Contrary to natural aging, the D-gal model led to an increase in cholesterol esters and the fraction of total esterified lipids in RBC membranes, and evoked significant changes in the secondary structure of the membrane proteins. Moreover, a significant decrease in the phosphorous level of blood plasma was specific for the D-gal model. On the other hand, natural aging induced stronger changes in the secondary structures of the proteins of the RBCs' interior. This work proves that research on the aging mechanism, especially in circulation-related diseases, should employ the D-gal model with caution. Nonetheless, the D-gal model enables to imitate age-related rheological alterations in RBCs, although they are partially derived from different changes observed in the RBC membrane at the molecular level.
Subject(s)
Aging, Premature/chemically induced , Aging/blood , Disease Models, Animal , Erythrocyte Membrane/chemistry , Galactose/toxicity , Spectroscopy, Fourier Transform Infrared , Spectrum Analysis, Raman , Aging, Premature/blood , Animals , Cytosol/chemistry , Erythrocyte Aging/drug effects , Erythrocyte Deformability/drug effects , Erythrocyte Indices/drug effects , Erythrocyte Membrane/drug effects , Free Radicals/toxicity , Galactose/pharmacology , Hemorheology/drug effects , Male , Mice , Mice, Inbred C57BL , Phosphorus/blood , Research DesignABSTRACT
BACKGROUND AND PURPOSE: The red blood cell fatty acid composition objectively reflects the long-term dietary intake of several fatty acids. In patients undergoing carotid endarterectomy, we explored whether red blood cell status of selected fatty acids related to symptomatic carotid artery disease. METHODS: We included patients with symptomatic (n=22) and asymptomatic (n=23) carotid artery disease. We determined all-C18:1 trans, linoleic acid (LA, C18:2n6), alpha-linolenic acid (C18:3n3), and the omega-3 index (sum of eicosapentaenoic [C20:5n3] and docosahexaenoic [C22:6n3] acids) in both red blood cells and carotid plaque phospholipids by gas-chromatography. RESULTS: In a multivariate logistic regression analysis, we only observed a significant association for LA, whose red blood cell status was inversely related to symptomatic carotid artery disease (odds ratio, 0.116 [95% CI, 0.022-0.607], P=0.011, for each 1-SD increase). A similar result was observed for LA in carotid plaque phospholipids. CONCLUSIONS: Cell membrane enrichment in LA, which reflects its intake, was inversely related to symptomatic carotid disease. This increases evidence supporting a favorable role of dietary LA in vascular health.
Subject(s)
Carotid Artery Diseases/epidemiology , Carotid Artery Diseases/metabolism , Erythrocyte Membrane/chemistry , Linoleic Acid/metabolism , Aged , Aged, 80 and over , Chromatography, Gas , Endarterectomy, Carotid , Erythrocyte Membrane/metabolism , Erythrocytes/chemistry , Fatty Acids/blood , Fatty Acids, Omega-3/blood , Female , Humans , Male , Phospholipids/blood , Plaque, Atherosclerotic , PrevalenceABSTRACT
Depressive disorder (DD) is a psychiatric disorder whose molecular basis is not fully understood. It is assumed that reduced consumption of fish and omega-3 fatty acids (FA) is associated with DD. Other lipids such as total cholesterol (TCH), LDL-, and HDL-cholesterols (LDL-CH, HDL-CH) also play a role in depression. The primary endpoint of the study was the effect of omega-3 FA on the severity of depression in children and adolescents. This study aimed to investigate the secondary endpoint, relationship between depressive disorder symptoms and lipid profile, LDL- and HDL-cholesterol subfractions, Paraoxonase 1 (PON1) activities, and erythrocyte membrane fluidity in 58 depressed children and adolescents (calculated by the statistical program on the effect size), as well as the effect of omega-3 FA on the monitored parameters. Depressive symptoms were assessed by the Children's Depression Inventory (CDI), lipid profile by standard biochemical procedures, and LDL- and HDL-subfractions by the Lipoprint system. Basic biochemical parameters including lipid profile were compared with levels in 20 healthy children and were in the physiological range. Improvement of symptoms in the group supplemented with a fish oil emulsion rich in omega-3 FA in contrast to omega-6 FA (emulsion of sunflower oil) has been observed. We are the first to report that omega-3 FAs, but not omega-6 FA, increase large HDL subfractions (anti-atherogenic) after 12 weeks of supplementation and decrease small HDL subfractions (proatherogenic) in depressed children. We found a negative correlation between CDI score and HDL-CH and the large HDL subfraction, but not LDL-CH subfractions. CDI score was not associated with erythrocyte membrane fluidity. Our results suggest that HDL-CH and its subfractions, but not LDL-CH may play a role in the pathophysiology of depressive disorder. The study was registered under ISRCTN81655012.
Subject(s)
Depressive Disorder/diet therapy , Fatty Acids, Omega-3/therapeutic use , Lipids/blood , Membrane Fluidity/physiology , Adolescent , Antidepressive Agents/therapeutic use , Blood Chemical Analysis , Chemical Fractionation , Child , Depressive Disorder/blood , Depressive Disorder/drug therapy , Depressive Disorder/pathology , Dietary Supplements , Double-Blind Method , Erythrocyte Membrane/chemistry , Erythrocyte Membrane/physiology , Fatty Acids, Omega-3/pharmacology , Female , Humans , Lipids/analysis , Lipoproteins/analysis , Lipoproteins/blood , Male , Severity of Illness Index , SlovakiaABSTRACT
BACKGROUND: The combination of radiotherapy (RT) and chemotherapy, as a standard treatment for breast cancer in the clinic, is unsatisfactory due to chemoradioresistance and severe side effects. METHODS AND RESULTS: To address these issues, a cancer cell-erythrocyte hybrid membrane-coated doxorubicin (DOX)-loaded gold nanocage (CM-EM-GNCs@DOX) was constructed for near-infrared light (NIR)-activated photothermal/radio/chemotherapy of breast cancer. CM-EM-GNCs@DOX inherited an excellent homologous target ability from the cancer cell membrane and an immune evasion capability from the erythrocyte membrane, together resulting in highly efficient accumulation in the tumor site with decreased clearance. Following the highly efficient uptake of CM-EM-GNCs@DOX in cancer cells, the RT efficacy was remarkably amplified due to the radiosensitization effect of CM-EM-GNCs@DOX, which reduced the needed radiotherapeutic dose. Importantly, with NIR irradiation, CM-EM-GNCs@DOX exerted a high photothermal effect, which not only ruptured CM-EM-GNCs@DOX to release DOX for precise and controllable chemotherapy, but also potentiated chemo/radiotherapy by photothermal therapy. CONCLUSION: Therefore, a highly efficient and safe combined photothermal/radio/chemotherapy approach was achieved in vitro and in vivo by CM-EM-GNCs@DOX, which provided a promising strategy for treating breast cancer.
Subject(s)
Breast Neoplasms/therapy , Cell Membrane/chemistry , Doxorubicin/administration & dosage , Nanostructures/chemistry , Phototherapy/methods , Animals , Antibiotics, Antineoplastic/administration & dosage , Antibiotics, Antineoplastic/pharmacokinetics , Breast Neoplasms/pathology , Cell Line, Tumor , Doxorubicin/pharmacokinetics , Erythrocyte Membrane/chemistry , Female , Gold/chemistry , Humans , Hyperthermia, Induced/methods , Infrared Rays , MCF-7 Cells , Membrane Fusion , Mice , Mice, Nude , Nanostructures/administration & dosage , Photosensitizing Agents/administration & dosage , Photosensitizing Agents/pharmacology , RAW 264.7 Cells , Xenograft Model Antitumor AssaysABSTRACT
BACKGROUND/OBJECTIVE: Membrane flexibility can be a determining factor in pathophysiological mechanisms of type 2 diabetes (T2D). As a cofactor of delta-5 desaturase (D5D) and delta-6 desaturase (D6D), and gene expression regulator, zinc may play a role modulating membrane flexibility by increasing membrane polyunsaturated fatty acids (PUFA) abundance. The objective of this study was to evaluate the effect of a 24-month zinc supplementation (30â¯mg elemental zinc) on membrane fatty acid composition in patients with T2D. SUBJECTS/METHODS: Sixty patients with T2D were evaluated. Thirty were randomly assigned to the zinc supplemented group and thirty to the placebo group. Fatty acid composition in red blood cell (RBC) membranes was determined by gas chromatography. Expression of gene encoding for D5D (FADS1), and D6D (FADS2) were evaluated in peripheral blood mononuclear cells by real-time polymerase chain reaction. RESULTS: After 24 months of supplementation, a greater abundance of docosapentaenoic acid (C22:5 n-3), arachidonic acid (C20:4 n-6), adrenic acid (C22:4 n-6), and total n-6 PUFA was found (p = 0.001, p = 0.007, p = 0.033, p = 0.048, respectively). The unsaturated fatty acids/saturated fatty acids ratio, and unsaturation index was increased in the zinc supplemented group at month 24 (p = 0.003 and p â¯=â¯0.000, respectively). FADS1 gene was upregulated in the zinc group in relation to placebo at month 12 (p = 0.020). CONCLUSIONS: Supplementation with 30â¯mg/d elemental zinc during 24 months in patients with T2D had an effect on the composition of RBC membranes increasing PUFA abundance and in turn, improving membrane flexibility. This effect may be mediated by induction of D5D gene expression.
Subject(s)
Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/diet therapy , Erythrocyte Membrane/drug effects , Fatty Acids/blood , Zinc/pharmacology , Adult , Aged , Delta-5 Fatty Acid Desaturase , Dietary Supplements , Erythrocyte Membrane/chemistry , Fatty Acid Desaturases/genetics , Fatty Acids/chemistry , Fatty Acids, Unsaturated/blood , Fatty Acids, Unsaturated/chemistry , Female , Humans , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/physiology , Male , Middle Aged , PlacebosABSTRACT
Combination photothermal therapy (PTT)/chemotherapy has become an emerging cancer treatment strategy in recent years. However, one of the important challenges in the development of nanomedicines is escaping immune recognition and the phagocytosis by the reticuloendothelial system (RES) to ultimately maximize tumor accumulation. In this work, a cell membrane-coated magnetically targeted drug delivery nanosystem was developed for synergistic PTT/chemotherapy of cancer. Importantly, this nanosystem can cleverly escape identification and clearance from the immune system, effectively prolong the blood circulation time and accurately accumulate in the target tumor tissues. This provides a new strategy to realize extraordinary antitumor effect by a unique design with cell membrane cloaking, magnetic targeting, drug delivery and synergistic PTT/chemotherapy.
Subject(s)
Antibiotics, Antineoplastic/pharmacology , Doxorubicin/pharmacology , Erythrocyte Membrane/chemistry , Nanoparticles/chemistry , Phototherapy , Polylactic Acid-Polyglycolic Acid Copolymer/chemistry , Animals , Antibiotics, Antineoplastic/chemistry , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Doxorubicin/chemistry , Drug Delivery Systems , Drug Screening Assays, Antitumor , Female , Magnetic Phenomena , Mammary Neoplasms, Experimental/diagnostic imaging , Mammary Neoplasms, Experimental/drug therapy , Mice , Mice, Inbred BALB C , Molecular Structure , Optical Imaging , Particle Size , Surface PropertiesABSTRACT
Photothermal therapy (PTT), which involves an increase in temperature triggered only by light signals at tumor sites to remove cancer cells, has been considered an attractive strategy in cancer therapy. Nevertheless, the in vivo applications of photosensitizer-based PTT are limited due to the poor biocompatibility of photothermal agents. Employing red blood cell (RBC) membranes to encapsulate photothermal agents can solve this issue, but the extra surface coating will suppress heat dissipation, which is unfavorable for the subsequent treatment. Herein, biomimetic nano-capsules have been fabricated for light signal-activated cancer therapy by encapsulating photocatalyst titanium dioxide colloid and photothermal agent gold nanorods (Au NRs) in erythrocyte membrane vesicles. The fabricated Au/TiO2@RBC nano-capsules can achieve the controlled release of Au NRs upon the photocatalytic degradation of their surface cell membrane coatings, and generate therapeutic signals after the released Au NRs are irradiated by an NIR laser. Meanwhile, the reactive oxygen species (ROS) produced by photocatalysis are helpful for killing tumor cells photodynamically. Thus, the biomimetic nano-capsules prepared herein will contribute to the research and development in cancer cell therapy.
Subject(s)
Breast Neoplasms/therapy , Erythrocyte Membrane/chemistry , Hyperthermia, Induced , Metal Nanoparticles/administration & dosage , Photochemotherapy , Photosensitizing Agents/administration & dosage , Phototherapy , Biomimetics , Capsules , Cell Proliferation , Female , Gold/chemistry , Humans , Metal Nanoparticles/chemistry , Reactive Oxygen Species , Titanium/chemistry , Tumor Cells, CulturedABSTRACT
Delivery efficiencies of theranostic nanoparticles (NPs) based on passive tumor targeting strongly depend either on their blood circulation time or on appropriate modulations of the tumor microenvironment. Therefore, predicting the NP delivery efficiency before and after a tumor microenvironment modulation is highly desirable. Here, we present a new erythrocyte membrane-camouflaged magnetofluorescent nanocarrier (MMFn) with long blood circulation time (92 h) and high delivery efficiency (10% ID for Ehrlich murine tumor model). MMFns owe their magnetic and fluorescent properties to the incorporation of manganese ferrite nanoparticles (MnFe2O4 NPs) and IR-780 (a lipophilic indocyanine fluorescent dye), respectively, to their erythrocyte membrane-derived camouflage. MMFn composition, morphology, and size, as well as optical absorption, zeta potential, and fluorescent, magnetic, and magnetothermal properties, are thoroughly examined in vitro. We then present an analytical pharmacokinetic (PK) model capable of predicting the delivery efficiency (DE) and the time of peak tumor uptake (tmax), as well as changes in DE and tmax due to modulations of the tumor microenvironment, for potentially any nanocarrier. Experimental PK data sets (blood and tumor amounts of MMFns) are simultaneously fit to the model equations using the PK modeling software Monolix. We then validate our model analytical solutions with the numerical solutions provided by Monolix. We also demonstrate how our a priori nonmechanistic model for passive targeting relates to a previously reported mechanistic model for active targeting. All in vivo PK studies, as well as in vivo and ex vivo biodistribution studies, were conducted using two noninvasive techniques, namely, fluorescence molecular tomography (FMT) and alternating current biosusceptometry (ACB). Finally, histopathology corroborates our PK and biodistribution results.
Subject(s)
Drug Carriers/chemistry , Erythrocyte Membrane/chemistry , Ferric Compounds/chemistry , Fluorescent Dyes/chemistry , Magnetic Iron Oxide Nanoparticles/chemistry , Magnets/chemistry , Manganese Compounds/chemistry , Photothermal Therapy/methods , Animals , Carcinoma, Ehrlich Tumor/drug therapy , Disease Models, Animal , Drug Carriers/pharmacokinetics , Female , Ferric Compounds/pharmacokinetics , Fluorescent Dyes/pharmacokinetics , Hyperthermia, Induced/methods , Manganese Compounds/pharmacokinetics , Mice , Particle Size , Theranostic Nanomedicine/methods , Tissue Distribution , Tumor Burden/drug effects , Tumor Microenvironment/drug effectsABSTRACT
The association between obesity and erythrocyte fatty acids (FAs) has been suggested; however, there have been no studies on the effects of onion peel extract (OPE) on the composition of erythrocyte FAs. This study aimed to investigate the effects of OPE on the composition of erythrocyte FAs in overweight and obese subjects. This was a randomized, double-blind, and placebo-controlled trial conducted in overweight and obese Korean subjects. The placebo and OPE groups were taking placebo capsule or OPE capsule twice per day for 12 weeks. Body composition and fat distribution were measured using dual-energy X-ray absorptiometry. The OPE group showed significantly reduced body weight, body mass index, body fat mass, and percentage of body fat mass. After 12 weeks, eicosapentaenoic acid and monounsaturated FAs of the placebo group were significantly lower at baseline. Consumption of OPE ameliorated the decreasing polyunsaturated n-3 polyunsaturated FA (PUFA) n-3 and increasing PUFA n-6, which prevented an increased n-6/n-3 ratio. The changes in arm fat percentage (ARFATP), trunk fat percentage, and total fat percentage (FATP) were negatively correlated with the change in PUFA n-3. In addition, increased erythrocyte docosahexaenoic acid was associated with decreased ARFATP and FATP. These results suggest that OPE has beneficial effects on obesity by regulating erythrocyte n-6/n-3 ratio and preventing fat accumulation in various body regions.
Subject(s)
Erythrocyte Membrane/chemistry , Fatty Acids, Omega-3/chemistry , Obesity/blood , Onions/chemistry , Overweight/blood , Plant Extracts/pharmacology , Adiposity , Adult , Body Mass Index , Body Weight , Double-Blind Method , Fatty Acids, Omega-6/chemistry , Humans , Middle Aged , Republic of KoreaABSTRACT
PURPOSE: Depression clinical trials are increasingly studying biomarkers to predict and monitor response to treatment. Assessment of biomarkers may reveal subsets of patients who are responsive to nutraceutical treatment, which may facilitate a personalized approach to treating depression. METHODS: This is a post hoc analysis of an 8-week, double-blind, randomized, controlled trial (n = 158) investigating a combination nutraceutical comprising Omega-3 (EPA 1 g/DHA 656 mg), SAMe, zinc, 5-HTP, folinic acid, and co-factors versus placebo for the treatment of Major Depressive Disorder. The study explored levels of polyunsaturated fatty acids, folate, vitamin B12, zinc, homocysteine, and BDNF as possible predictors and correlates of response to nutraceutical supplementation. RESULTS: Concentrations of EPA and DHA in red cell membranes increased in response to treatment and were significantly correlated with a decrease in depressive symptoms during active treatment (p = 0.003 and p = 0.029; respectively). Higher baseline levels of omega-6 fatty acid also correlated with depression reduction in the active treatment group ( p = 0.011). No other biomarkers were associated with a lessening of depressive symptoms. CONCLUSION: Changes in fatty acid levels resulting from a nutraceutical combination containing EPA and DHA provide a response biomarker in treating depression.
Subject(s)
Depressive Disorder, Major/diet therapy , Dietary Supplements , Docosahexaenoic Acids/analysis , Eicosapentaenoic Acid/analysis , Adult , Biomarkers/analysis , Double-Blind Method , Erythrocyte Membrane/chemistry , Female , Humans , MaleABSTRACT
BACKGROUND & AIMS: Evidence-based concepts to prevent breast cancer in women with BRCA1/2 mutations are limited. Adherence to a Mediterranean diet (MedD) has been associated with a lower risk for breast cancer, possibly due to a favorable fatty acid (FA) intake. Here, we studied in an at-risk population the effect of a lifestyle intervention that included the MedD on FA composition in red blood cell membranes (RBCM). METHODS: Data derived from the German multicenter trial LIBRE, from which 68 women were randomized into an intervention group (IG) trained for MedD and increased physical activity for 12 months, and a usual care control group (CG). Adherence to the diet was assessed after 3 and 12 months using the validated Mediterranean Diet Adherence Screener (MEDAS) and a food frequency questionnaire. RBCM FA were analyzed by gas chromatography with mass spectrometry. RESULTS: The MEDAS was increased in both groups after 3 months (IG: P < 0.001; CG: P = 0.004), and remained increased only in the IG after 12 months (P < 0.001). The food frequency questionnaire revealed an increased intake of omega-3 (n-3) FA at month 3 and month 12 in the IG (both P < 0.01), but not in the CG, in which intake of energy, protein and saturated FA decreased. In both groups n-6 FA in the RBCM decreased (P < 0.001), while n-9 FA increased (P < 0.001) and n-3 FA were unchanged. Women with higher consumption of fish had higher amounts of n-3 fatty acids in the RBCM. The MEDAS was inversely correlated with n-6 fatty acids. CONCLUSIONS: The RBCM FA composition was associated with dietetic parameters related to the MedD. Adherence to the MedD resulted in an altered, likely favorable FA composition. Our data suggest selected FA as biomarkers to monitor compliance to a dietetic intervention such as the MedD. CLINICAL TRIAL REGISTRY: The trial is registered at ClinicalTrials.gov (reference: NCT02087592).
Subject(s)
Breast Neoplasms/prevention & control , Diet, Mediterranean/statistics & numerical data , Erythrocyte Membrane/chemistry , Fatty Acids/blood , Patient Compliance/statistics & numerical data , Adult , Biomarkers/blood , Diet Surveys , Fatty Acids, Omega-3/analysis , Fatty Acids, Omega-6/analysis , Female , Humans , Life Style , Middle AgedABSTRACT
Conventional systemic chemotherapy leads to poor therapeutic outcomes at moments in cancer therapy because the nontargeting anticancer drug release results in adverse effects and consequently drug resistance. The combination therapeutic strategy provides an alternative way to solve the conundrums. Herein, drug delivery systems with a rational design and tumor-targeting abilities become the ideal carriers for combinatorial therapy. IR780 iodide possesses near-infrared fluorescence intensity for fluorescence imaging (FI) and photothermal conversion for photoacoustic imaging (PAI), which also can be employed for tumor phototherapy (including photothermal therapy and photodynamic therapy). However, hydrophobicity and rapid elimination in vivo limit its biomedical applications. Furthermore, the hydrophobicity and high crystallization of IR780 result in poor drug-loading capacity and low stability. In this study, the high-pressure homogenization method was utilized for hydrophobic molecular IR780 and DTX coloading to construct IR780/DTX-PCEC nanoparticles which exhibit narrow size distribution and satisfactory drug-loading capacity. With further erythrocyte membrane [red blood cell (RBC)] camouflaging, the obtained IR780/DTX-PCEC@RBC nanoparticles present desired stability and prolonged circulation time in vivo. Additionally, the IR780/DTX-PCEC@RBC nanoparticles not only can be employed as a FI/PAI dual model imaging probe but also exhibit the property for phototherapy and chemotherapy of tumors. Based on the therapeutic outcome of combination therapy, the IR780/DTX-PCEC@RBC nanoparticles can serve as promising FI- and PAI-guided photo-chemo combination therapy agents for the future treatment of breast cancer.
Subject(s)
Breast Neoplasms/drug therapy , Digitoxigenin/chemistry , Drug Delivery Systems/methods , Erythrocyte Membrane/chemistry , Indoles/chemistry , Nanoparticles/chemistry , Photochemotherapy/methods , Polymers/chemistry , Animals , Apoptosis/drug effects , Cell Survival/drug effects , Digitoxigenin/pharmacokinetics , Drug Liberation , Female , Humans , MCF-7 Cells , Mice , Mice, Inbred BALB C , Mice, Nude , Optical Imaging , Tissue Distribution , Tumor Burden/drug effects , Xenograft Model Antitumor AssaysABSTRACT
Cu2-xSe nanoparticles (Cu2-xSeNPs) were camouflaged with a red blood cell membrane (RBC) to create nanoparticles with improved biocompatibility, longer blood retention times, excellent absorption properties, superior photothermal conversion efficiency (67.2%) and singlet oxygen production capabilities for the synergistic photothermal and photodynamic therapy of cancer in the second near-infrared (NIR-II) window.
Subject(s)
Antineoplastic Agents/therapeutic use , Erythrocyte Membrane/chemistry , Nanoparticles/therapeutic use , Neoplasms/drug therapy , Animals , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/radiation effects , Antineoplastic Agents/toxicity , Cell Line, Tumor , Copper/chemistry , Hot Temperature , Humans , Hyperthermia, Induced/methods , Infrared Rays , Mice , Nanoparticles/chemistry , Nanoparticles/radiation effects , Nanoparticles/toxicity , Photochemotherapy/methods , RAW 264.7 Cells , Selenium/chemistry , Singlet Oxygen/metabolism , Xenograft Model Antitumor AssaysABSTRACT
Conventional anti-tumour chemotherapy is facing the challenges of poor specificity, high toxicity and drug resistance. Tumour microenvironment (TME) plays a critical role in tumour development and drug resistance. To address this problem, we constructed a novel anti-tumour nanoparticle platform RBC@BPQDs-DOX/KIR, black phosphorus nanoparticle quantum dots (BPQDs) with one of the chemotherapeutics (doxorubicin, DOX) and an anti-inflammatory traditional Chinese medicine active component (Kirenol, KIR). Red blood cell membrane (RBCm) vesicles were used as the shell to envelop several nanocores. The combination of DOX and KIR may promote therapeutic efficacy, at which the anti-apoptotic effect of the tumour cells was inhibited (by downregulating Bcl-2 and upregulating Bax) and the tumour progression-related inflammatory factors, such as tumour necrosis factor α (TNF-α) and interleukin-6 (IL-6) were downregulated. Furthermore, TME was remodelled and the anti-tumour effect of DOX was magnified. RBCm imparts high biocompatibility and enhanced permeability and retention (EPR) effects to RBC@BPQDs-DOX/KIR, thus enhancing its tumour passively targetability. Overall, the RBCm-camouflaged drug delivery system RBC@BPQDs-DOX/KIR as a promising therapy for targeted chemotherapeutics and anti-inflammatory therapeutics may provide a specific and highly efficient anti-tumour treatment choice.
Subject(s)
Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/pharmacology , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Erythrocyte Membrane/chemistry , Phosphorus/chemistry , Quantum Dots/chemistry , Animals , Anti-Inflammatory Agents/pharmacokinetics , Antineoplastic Agents/pharmacokinetics , Apoptosis/drug effects , Cell Line, Tumor , Diterpenes/chemistry , Diterpenes/pharmacokinetics , Diterpenes/pharmacology , Doxorubicin/chemistry , Doxorubicin/pharmacokinetics , Doxorubicin/pharmacology , Drug Liberation , Female , Humans , Materials Testing , Mice , Tissue Distribution , Xenograft Model Antitumor AssaysABSTRACT
Cell membrane coating has emerged as an intriguing biomimetic strategy to endow nanomaterials with functions and properties inherent to source cells for various biomedical applications. Hybrid membrane of different types of cells could be coated onto nanoparticle surface to achieve additional functions. Herein, we fused red blood cell (RBC) membrane together with MCF-7â¯cell membrane and fabricated an erythrocyte-cancer (RBC-M) hybrid membrane-camouflaged melanin nanoparticle (Melanin@RBC-M) platform for enhancing therapeutic efficacy of photothermal therapy (PTT). The fused RBC-M hybrid membrane vesicles retained both RBC and MCF-7â¯cell membrane proteins and the resultant Melanin@RBC-M exhibited prolonged blood circulation and homotypic targeting to source MCF-7â¯cells simultaneously. Interestingly, increasing MCF-7 membrane components in RBC-M significantly enhanced the homotypic targeting function of Melanin@RBC-M while increasing RBC membrane components in RBC-M effectively reduced the cellular uptake of Melanin@RBC-M by macrophages and improved their circulation time in the blood. After intravenous injection into MCF-7 tumor-bearing athymic nude mice, Melanin@RBC-M with 1:1 membrane protein weight ratio of RBC to MCF-7 exhibited significantly higher tumor accumulation and better PTT efficacy compared with other Melanin@RBC-M with different membrane protein weight ratios as well as pristine melanin nanoparticles, due to the optimal balance between prolonged blood circulation and homotypic targeting. In addition, in vitro photoacoustic results revealed that Melanin@RBC-M had a photoacoustic signal enhancement with the increase of nanoparticle size (64â¯ââ¯148â¯nm) and the photoacoustic amplitudes increased linearly with nanoparticle concentration at the excitation wavelength ranged from 680â¯nm to 800â¯nm, which could be used for quantification of Melanin@RBC-M in vivo. Looking forward, coating hybrid membrane onto nanoparticles could add flexibility and controllability in enhancing nanoparticles functionality and offer new opportunities for biomedical applications.
Subject(s)
Erythrocyte Membrane/chemistry , Hyperthermia, Induced/methods , Melanins/therapeutic use , Nanoparticles/therapeutic use , Neoplasms/therapy , Animals , Erythrocyte Membrane/transplantation , Humans , MCF-7 Cells , Melanins/chemistry , Mice, Nude , Nanoparticles/chemistry , Neoplasms/chemistryABSTRACT
BACKGROUND & AIMS: The association between circulating n-3 polyunsaturated fatty acid (PUFA) biomarkers and incident type 2 diabetes in Asian populations remains unclear. We aimed to examine the association of erythrocyte n-3 PUFA with incident type 2 diabetes in a Chinese population. METHODS: A total of 2671 participants, aged 40-75 y, free of type 2 diabetes at baseline, were included in the present analysis. Incident type 2 diabetes cases (n = 213) were ascertained during median follow-up of 5.6 years. Baseline erythrocyte fatty acids were measured by gas chromatography. We used multivariable Cox regression models to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of type 2 diabetes across quartiles of erythrocyte n-3 PUFA. RESULTS: After adjustment for potential confounders, HRs (95% CIs) of type 2 diabetes were 0.68 (0.47, 1.00), 0.77 (0.52, 1.15), and 0.63 (0.41, 0.95) in quartiles 2-4 of docosapentaenoic acid (C22:5n-3) (P-trend = 0.07), compared with quartile 1; and 1.08 (0.74, 1.60), 1.03 (0.70, 1.51), and 0.57 (0.38, 0.86) for eicosapentaenoic acid (C20:5n-3) (P-trend = 0.007). No association was found for docosahexaenoic acid (C22:6n-3) or alpha-linolenic acid (C18:3n-3). CONCLUSIONS: Erythrocyte n-3 PUFA from marine sources (C22:5n-3 and C20:5n-3), as biomarkers of dietary marine n-3 PUFA, were inversely associated with incident type 2 diabetes in this Chinese population. Future prospective investigations in other Asian populations are necessary to confirm our findings.